An array of PPARγ ligands can modulate tumour growth and progression by influencing the WNT, MAPK, NF‐kB and TGF‐β signalling pathways in lung cancer cells and stromal cells, in a PPARγ‐dependent fashion. This evidence concerns the gene PPARG and lung cancer.